Saratoga Research & Investment Management Bristol Myers Squibb CO Transaction History

Saratoga Research & Investment Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 17, 2024	BUY	$47.98 - $54.4 $177,717 - $201,497	3,704 New	3,704 $200,000
Q3 2023 Nov 09, 2023	SELL	$57.89 - $64.73 $11,404 - $12,751	-197 Reduced 5.04%	3,713 $215,000
Q2 2023 Jul 24, 2023	BUY	$63.71 - $70.74 $573 - $636	9 Added 0.23%	3,910 $250,000
Q3 2022 Oct 31, 2022	SELL	$0.13 - $76.84 $2 - $1,383	-18 Reduced 0.46%	3,901 $277,000
Q1 2022 Apr 29, 2022	SELL	$61.48 - $73.72 $3,565 - $4,275	-58 Reduced 1.46%	3,919 $286,000
Q4 2021 Feb 08, 2022	SELL	$53.63 - $62.52 $73,258 - $85,402	-1,366 Reduced 25.57%	3,977 $248,000
Q2 2021 Aug 10, 2021	SELL	$61.91 - $67.42 $5,571 - $6,067	-90 Reduced 1.66%	5,343 $357,000
Q1 2021 Apr 12, 2021	SELL	$59.34 - $66.74 $8,901 - $10,011	-150 Reduced 2.69%	5,433 $343,000
Q3 2020 Oct 09, 2020	SELL	$57.43 - $63.64 $3,560 - $3,945	-62 Reduced 1.1%	5,583 $337,000
Q4 2019 Feb 05, 2020	SELL	$49.21 - $64.19 $3,198 - $4,172	-65 Reduced 1.14%	5,645 $362,000
Q3 2017 Oct 24, 2017	BUY	$55.23 - $63.74 $315,363 - $363,955	5,710	5,710 $364,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Saratoga Research & Investment Management, based on Form 13F filings with the SEC.

Stay updated on Saratoga Research & Investment Management with notifications on news.